Patents by Inventor Karen EBSWORTH

Karen EBSWORTH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
    Patent number: 11684606
    Abstract: The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: June 27, 2023
    Assignee: CHEMOCENTRYX, INC.
    Inventors: James J. Campbell, Karen Ebsworth, Antoni Krasinski, Venkat Reddy Mali, Jeffrey McMahon, Rajinder Singh, Ju Yang, Chao Yu, Penglie Zhang
  • COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR
    Publication number: 20230023075
    Abstract: The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
    Type: Application
    Filed: March 15, 2022
    Publication date: January 26, 2023
    Inventors: James J. CAMPBELL, Zhenhua MIAO, Thomas J. SCHALL, Israel CHARO, Shijie LI, Christine Marie JANSON, Rajinder SINGH, Karen EBSWORTH
  • METHODS OF TREATING GENERALIZED PUSTULAR PSORIASIS WITH AN ANTAGONIST OF CCR6 OR CXCR2
    Publication number: 20220280481
    Abstract: The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist.
    Type: Application
    Filed: November 16, 2021
    Publication date: September 8, 2022
    Inventors: James J. CAMPBELL, Karen EBSWORTH, Antoni KRASINSKI, Venkat Reddy MALI, Jeffrey McMAHON, Rajinder SINGH, Ju YANG, Chao YU, Penglie ZHANG
  • Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor
    Patent number: 11304952
    Abstract: The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: April 19, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: James J. Campbell, Zhenhua Miao, Thomas J. Schall, Israel Charo, Shijie Li, Christine Marie Janson, Rajinder Singh, Karen Ebsworth
  • Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2
    Patent number: 11207294
    Abstract: The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: December 28, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: James J. Campbell, Karen Ebsworth, Antoni Krasinski, Venkat Reddy Mali, Jeffrey McMahon, Rajinder Singh, Ju Yang, Chao Yu, Penglie Zhang
  • COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES
    Publication number: 20210322410
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.
    Type: Application
    Filed: May 24, 2021
    Publication date: October 21, 2021
    Inventors: James CAMPBELL, Israel CHARO, Thomas SCHALL, Karen EBSWORTH, Yu WANG, Yibin ZENG, Penglie ZHANG, Joanne TAN
  • COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES
    Publication number: 20200113898
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.
    Type: Application
    Filed: December 9, 2019
    Publication date: April 16, 2020
    Inventors: Karen EBSWORTH, Yu WANG, Yibin ZENG, Penglie ZHANG, Joanne TAN
  • Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-?4?7 integrin blocking antibodies
    Patent number: 10532051
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: January 14, 2020
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Karen Ebsworth, Yu Wang, Yibin Zeng, Penglie Zhang, Joanne Tan
  • METHODS OF TREATING GENERALIZED PUSTULAR PSORIASIS WITH AN ANTAGONIST OF CCR6 OR CXCR2
    Publication number: 20190209527
    Abstract: The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist.
    Type: Application
    Filed: January 7, 2019
    Publication date: July 11, 2019
    Inventors: James J. CAMPBELL, Karen EBSWORTH, Antoni KRASINSKI, Venkat Reddy MALI, Jeffrey McMAHON, Rajinder SINGH, Ju YANG, Chao YU, Penglie ZHANG
  • Combinations and Methods for Treating Inflammatory Bowel Disease Using a Combination Therapy of Small Molecule Inhibitors of C-C Chemokine Receptor 9 (CCR9) and Anti-alpha4beta7 Integrin Blocking Antibodies
    Publication number: 20160095921
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.
    Type: Application
    Filed: October 5, 2015
    Publication date: April 7, 2016
    Inventors: Karen EBSWORTH, Yu WANG, Yibin ZENG, Penglie ZHANG, Joanne TAN